We aim to stop Big Pharma from gaming the system to extend their monopolies at consumers’ expense. These resources contain information on key examples of patent abuse, as well as data on solutions to the issue and key legislation related to the topic.
Patent Thicketing White Paper
Patent thicketing involves bombarding the USPTO with patent applications over time in the hopes that enough are granted to prevent generic and biosimilar entry after the expiration of the original patents on a drug.
Patent Primer: What Is IPR?
Inter partes review (IPR), is a process created by the 2011 America Invents Act (AIA), provides a low-cost alternative to traditional patent litigation by using patent experts within the USPTO to take a second look at certain patents.
Fact Sheet: Namenda
Namenda is used to treat the confusion associated with Alzheimer’s Disease. An estimated 5.8 million Americans suffer from Alzheimer’s.
Fact Sheet: Humira
Humira is produced by drugmaker AbbVie and is used to treat primarily rheumatoid and psoriatic arthritis. In 2016, 4.4 million prescriptions for Humira were dispensed in the U.S.
Fact Sheet: Lantus
Lantus is a form of insulin produced by drugmaker Sanofi to help with the management of blood sugar levels due to Type I and some cases of Type II diabetes. Over 100 million Americans live with diabetes or pre-diabetes.
Fact Sheet: Suboxone
Suboxone is one of the key treatments for opioid addiction. Indivior produces the patented combination medication, which contains two other off-patent medications: buprenorphine and naloxone.
Infographic: Inter Partes Review
The vast majority of pharmaceutical industry patents are untouched by Inter Partes Review.
Fact Sheet: Section 101
Loosening the Patent Act’s Section 101 rules would encourage more patent abuse by pharmaceutical companies.